Interview with the Innovators Presents:
Antibody Drug Conjugate Therapy for the Treatment of HER2+ and HER2-Low mBC
As the breast cancer landscape continues to evolve with new research, it is imperative for advance practice providers and nurse navigators to have a comprehensive understanding of the disease state and side effect management. This educational series is intended to enhance the knowledge of advanced practice providers and navigators around a treatment option now available to a new patient population with mBC. The publishers of JONS and JHOP are pleased to present this 6-part video series featuring expert commentary: